新辅助化疗对胃癌14-3-3ε蛋白表达的影响

Effect of neoadjuvant chemotherapy on expression of 14-3-3 ε protein in gastric cancer

目的探讨新辅助化疗对胃癌14-3-3ε蛋白表达的影响。方法选取行根治性胃癌切除术患者72例,其中术前行新辅助化疗患者37例(A组),未行新辅助化疗患者35例(B组)。应用免疫组化法和Western blot检测2组患者胃癌组织中14-3-3ε蛋白表达量。分析不同临床因素与14-3-3ε蛋白表达的相关性。采用Kaplan-Meier生存曲线评估胃癌患者生存时间与14-3-3ε蛋白表达水平间的相关性,并对可能影响预后的临床病理因素进行单因素和多因素分析。结果 A组的14-3-3ε蛋白高表达率较B组低(P <0.01)。14-3-3ε蛋白表达水平与浸润程度(r=0.421, P=0.013)、淋巴结转移(r=0.495, P=0.003)和TNM分期(r=0.527, P=0.008)呈正相关。A组患者中,14-3-3ε蛋白高、低表达的生存曲线显著分离(P <0.05),而B组和所有患者中14-3-3ε蛋白低、高表达的生存曲线均无显著分离(P> 0.05)。多因素分析表明胃癌组织学分型、TNM分期和14-3-3ε蛋白表达水平与A组患者预后相关(P <0.05)。结论新辅助化疗可降低胃癌患者14-3-3ε蛋白表达,高表达14-3-3ε蛋白可能是患者预后不佳的一个风险因子。

AIM To investigate the effect of neoadjuvant chemotherapy on the expression of 14-3-3ε protein in gastric cancer. METHODS A total of 72 patients who underwent radical gastric cancer resection were collected, including 37 patients receiving preoperative neoadjuvant chemotherapy(group A) and 35 patients without neoadjuvant chemotherapy(group B). Immunohistochemistry and Western blot were used to detect the expression of 14-3-3ε protein in gastric cancer. The correlation between different clinical factors and 14-3-3ε protein expression was analyzed. The Kaplan-Meier survival curve was used to evaluate the correlation between the survival time of gastric cancer patients and the expression level of 14-3-3ε protein, and to conduct univariate and multivariate analysis of clinicopathological factors that may affect the prognosis. RESULTS The high expression rate of 14-3-3ε protein in group A was lower than that in group B(P < 0.01). The expression level of 14-3-3ε protein was positively correlated with tumor invasion depth(r = 0.421, P = 0.013), lymph node metastasis(r = 0.495, P = 0.003) and TNM stage(r = 0.527, P = 0.008). In the group A, the survival curve of patients with high or low 14-3-3ε protein expression was significantly separated(P < 0.05), while there was no significant difference in the survival curve with low or high 14-3-3ε protein expression in group B or all patients(P > 0.05). Multivariate analysis showed that histological type, TNM stage and 14-3-3ε protein expression level were related to the prognosis of patients in group A(P < 0.05). CONCLUSION Neoadjuvant chemotherapy can reduce the expression of 14-3-3ε protein in gastric cancer. High expression of 14-3-3ε protein may be a risk factor for poor prognosis in patients.